Viktoria Betin

Viktoria Betin is a Principal Scientist at Dyno Therapeutics since March 2024, having previously held similar roles at ImmuneID from March 2021 to July 2023 and Flagship Pioneering from September 2019 to March 2021. Viktoria's expertise includes leading scientific teams as a Senior Scientist II and conducting innovative research as a Postdoctoral Associate at the Broad Institute of MIT and Harvard, where significant contributions were made in Dual RNA-Seq studies of Mycobacterium tuberculosis. Viktoria's academic background encompasses a PhD and MA in Biology from Harvard University, as well as a BA in Molecular and Cell Biology from the University of California, Berkeley. During graduate studies, Viktoria excelled in teaching, receiving certificates of teaching excellence and engaging undergraduates in discussions on global health and infectious diseases.